Elutia, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05479K1060
USD
0.69
0.05 (7.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Elutia, Inc. stock-summary
stock-summary
Elutia, Inc.
Pharmaceuticals & Biotechnology
Aziyo Biologics, Inc. is a commercial-stage regenerative medicine company. The Company is focused on the development of products for patients undergoing surgery, concentrating on patients receiving implantable medical devices. Its products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets. The Company's products include CanGaroo, ProxiCor, Tyke, VasCure, FiberCel, ViBone, OsteGro V and SimpliDerm. The Company fulfill tissue processing contracts through its contract manufacturing services at its Richmond, California facility.
Company Coordinates stock-summary
Company Details
12510 PROSPERITY DRIVE, SUITE 370 , SILVER SPRING MD : 20904
stock-summary
Tel: 1 240 2471143
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (3.69%)

Foreign Institutions

Held by 8 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Rakin
Chairman of the Board
Mr. Ron Lloyd
President, Chief Executive Officer, Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 80 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.62

stock-summary
Return on Equity

67.24%

stock-summary
Price to Book

-1.90